Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

$48.4 million in cash at the end of Q2 2023 expected to provide operating runway into 2025Fully prepaid and retired debt facilityAuthorized $7.5 million stock repurchase programLA JOLLA, Calif.--(BUSINESS WIRE)--$EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding...

Related Keywords

Japan ,United States ,Australia ,American ,Japanese ,Australian ,Michael Moore ,Maple Fung ,Head Of Corporate Communications ,American Association Of Immunologists ,Clinical Development ,Nasdaq ,Biocon ,Meeting Of The European Society For Blood ,Equillium Inc ,Exchange Commission ,Ono Pharmaceutical Co Ltd ,Bruce Steel ,Second Quarter ,Chief Medical Officer ,American Association ,Annual Meeting ,European Society ,Marrow Transplantation ,Upcoming Milestones ,Multi Cytokine Platform ,Biocon Limited ,Private Securities Litigation Reform Act ,Consolidated Statements ,Investor Relations Officer ,Corporate Communications ,